Table 3 Treatment-emergent adverse events of the SS.

	0.23 mg/kg/week (n=59) n (%)	0.46 mg/kg/week (n=59) n (%)	Total (n=118) n (%)
TEAEs	49 (83.1)	52 (88.1)	101 (85.6)
TRAEs	14 (23.7)	20 (33.9)	34 (28.8)
SAEs	5 (8.5)	7 (11.9)	12 (10.2)
Treatment suspension due to TEAEs	1 (1.7)	1 (1.7)	2 (1.7)
TEAEs occurring in ≥5% of subjects in any group
Upper respiratory tract infection	32 (54.2)	31 (52.5)	63 (53.4)
Fever	10 (17.0)	11 (18.6)	21 (17.8)
Cough	7 (11.9)	11 (18.6)	18 (15.3)
Elevated blood insulin	8 (13.6)	10 (17.0)	18 (15.3)
Rhinitis	6 (10.2)	7 (11.9)	13 (11.0)
Rash	1 (1.7)	6 (10.2)	7 (5.9)
Respiratory infection	5 (8.5)	2 (3.4)	7 (5.9)
Vomit	4 (6.8)	3 (5.1)	7 (5.9)
Tonsilitis	2 (3.4)	4 (6.8)	6 (5.1)
Abdominal pain	3 (5.1)	3 (5.1)	6 (5.1)
Bronchitis	1 (1.7)	4 (6.8)	5 (4.2)
Elevated blood glucose	4 (6.8)	1 (1.7)	5 (4.2)
Head injury	0 (0.0)	5 (8.5)	5 (4.2)
Pneumonia	3 (5.1)	0 (0.0)	4 (3.4)
Sneezing	0 (0.0)	3 (5.1)	3 (2.5)
Indigestion	3 (5.1)	0 (0.0)	3 (2.5)

SAE: Serious adverse event; SS: Safety set; TEAE: Treatment-emergent adverse event; TRAE: Treatment-related adverse event.